Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus price objective of $11.50 for the company and are predicting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Parnell Pharmaceuticals Holdings an industry rank of 160 out of 265 based on the ratings given to its competitors.

Shares of Parnell Pharmaceuticals Holdings (NASDAQ:PARN) traded down 0.3014% during midday trading on Friday, hitting $1.4556. The stock had a trading volume of 3,945 shares. The firm has a 50-day moving average price of $1.50 and a 200-day moving average price of $1.72. Parnell Pharmaceuticals Holdings has a 1-year low of $1.34 and a 1-year high of $4.89. The firm’s market cap is $21.37 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

A hedge fund recently raised its stake in Parnell Pharmaceuticals Holdings stock. BlackRock Group LTD raised its position in shares of Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN) by 2.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 217,196 shares of the company’s stock after buying an additional 5,200 shares during the period. BlackRock Group LTD owned approximately 1.64% of Parnell Pharmaceuticals Holdings worth $354,000 at the end of the most recent reporting period.

About Parnell Pharmaceuticals Holdings

Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets.

5 Day Chart for NASDAQ:PARN

Get a free copy of the Zacks research report on Parnell Pharmaceuticals Holdings (PARN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Parnell Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parnell Pharmaceuticals Holdings Ltd and related companies with's FREE daily email newsletter.